FIT Biotech Overview

  • Founded
  • 1995
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • IPO
  • Latest Deal Amount
  • $20.2M
Latest Deal Amount

FIT Biotech General Information

Description

FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • Biokatu 8
  • 33520 Tampere
  • Finland
+358 03 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

FIT Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. IPO 01-Jul-2015 $20.2M 000.00 000.00 Completed Generating Revenue
1. Early Stage VC 29-Jun-2006 00.000 00.000 Completed Product Development
To view FIT Biotech’s complete valuation and funding history, request access »

FIT Biotech Patents

FIT Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20110171255-A1 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant Granted 23-May-2008 000000000 0
US-9474800-B2 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant Active 23-May-2008 000000000 0
AU-2009248735-A1 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant Granted 23-May-2008 000000000
CA-2724570-A1 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant Abandoned 23-May-2008 000000000
AU-2009248735-B2 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant Ceased 23-May-2008 A61K39/39
To view FIT Biotech’s complete patent history, request access »

FIT Biotech Executive Team (3)

Name Title Board Seat Contact Info
Erkki Pekkarinen Chief Executive Officer
James Kuo MD Chief Executive Officer
You’re viewing 2 of 3 executive team members. Get the full list »

FIT Biotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

FIT Biotech Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 23-Jan-2003 0000000000 Other Devices and Supplies 000000 00
To view FIT Biotech’s complete acquisitions history, request access »